Abstract
Gonadotropin-releasing hormone antagonists (GnRH-ant) are routinely used to prevent premature luteinizing hormone (LH) surges in women undergoing in vitro fertilization (IVF) programs. GnRH-ant act by competitively binding GnRH receptors (GnRHr), leading to rapid pituitary suppression. GnRH-ant can also block extrapituitary GnRHr, including those present in ovary, placenta, and endometrium. A full understanding of the functional roles played by extrapitutary GnRHr, along with a better characterization of the possible reproductive consequences of their blockage may aid the refinement of controlled ovarian stimulation (COS) protocols using GnRHant. This review summarizes current research in the area, especially focusing on the possible impact of GnRH-ant on steroidogenesis, folliculogenesis and endometrial receptivity.
Keywords: GnRH, GnRH antagonists, Steroidogenesis, Folliculogenesis, Endometrium, In Vitro Fertilization, ovary, placenta, controlled ovarian stimulation (COS), endometrial receptivity
Current Pharmaceutical Design
Title: Extrapituitary Actions of GnRH Antagonists: Prospects for in vitro Fertilization Programs
Volume: 18 Issue: 3
Author(s): Gianna Gabriella Impicciatore and Gian Mario Tiboni
Affiliation:
Keywords: GnRH, GnRH antagonists, Steroidogenesis, Folliculogenesis, Endometrium, In Vitro Fertilization, ovary, placenta, controlled ovarian stimulation (COS), endometrial receptivity
Abstract: Gonadotropin-releasing hormone antagonists (GnRH-ant) are routinely used to prevent premature luteinizing hormone (LH) surges in women undergoing in vitro fertilization (IVF) programs. GnRH-ant act by competitively binding GnRH receptors (GnRHr), leading to rapid pituitary suppression. GnRH-ant can also block extrapituitary GnRHr, including those present in ovary, placenta, and endometrium. A full understanding of the functional roles played by extrapitutary GnRHr, along with a better characterization of the possible reproductive consequences of their blockage may aid the refinement of controlled ovarian stimulation (COS) protocols using GnRHant. This review summarizes current research in the area, especially focusing on the possible impact of GnRH-ant on steroidogenesis, folliculogenesis and endometrial receptivity.
Export Options
About this article
Cite this article as:
Gabriella Impicciatore Gianna and Mario Tiboni Gian, Extrapituitary Actions of GnRH Antagonists: Prospects for in vitro Fertilization Programs, Current Pharmaceutical Design 2012; 18 (3) . https://dx.doi.org/10.2174/138161212799040358
DOI https://dx.doi.org/10.2174/138161212799040358 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Immunotherapies for Renal Cell Carcinoma
Current Molecular Pharmacology Multidrug Resistance and Cancer: The Role of the Human ABC Transporter ABCG2
Current Protein & Peptide Science Glucocorticoids Selectively Inhibit Paclitaxel-Induced Apoptosis: Mechanisms and Its Clinical Impact
Current Medicinal Chemistry TWIST1 Gene: First Insights in Felis catus
Current Genomics Evolving Role of Radiopharmaceuticals in Hepatocellular Carcinoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Complications of Paget Bone Disease: A Study of 69 Patients
Current Rheumatology Reviews The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
Current Cancer Drug Targets Therapeutics Based on microRNA: A New Approach for Liver Cancer
Current Genomics Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Current Pharmaceutical Design Recent Developments of Phototherapy Based on Graphene Family Nanomaterials
Current Medicinal Chemistry Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics LncRNAs as Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy
Current Cancer Drug Targets MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
Current Pharmaceutical Design Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism Anticancer Potential of Doxorubicin in Combination with Green-Synthesized Silver Nanoparticle and its Cytotoxicity Effects on Cardio-Myoblast Normal Cells
Anti-Cancer Agents in Medicinal Chemistry Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent
Current Molecular Pharmacology DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry Anti-carcinogenic Effect of Cathepsin K Inhibitor, Odanacatib with a Low Dose of Cisplatin Against Human Breast Carcinoma MCF-7 and MDA-MB231 Cells
Current Cancer Therapy Reviews